BioDelivery Sciences (BDSI) Misses Q4 EPS by 36c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to BioDelivery Sciences (BDSI) Misses Q4 EPS by 36c

Bunavail and Belbuca Should Allow BioDelivery Sciences (BDSI) To Outperform - Piper Jaffray

March 11, 2016 7:51 AM EST

Piper Jaffray analyst, David Amsellem, provided an update on BioDelivery Sciences (NASDAQ: BDSI) after the company reported 4Q15. Bunavail access continues to improve and the analyst is positive on the outlook reiterating his Overweight rating.

BioDelivery Sciences reported 4Q15 EPS of $0.19 on revenues of $32M (inclusive of a $30M milestone from Endo associated with the approval of Belbuca in October 2015). Sales of Bunavail, the company's buccal film form of buprenorphine/naloxone for opioid dependence, were $1.5M, and Bunavail now has Medicare/Medicaid access in 26 states. Given the... More